Furosemide 10mg/ml Solution for Injection or Infusion
... Intravenous furosemide must be injected or infused slowly; a rate of 4 mg per minute must not be exceeded. In patients with severe impairment of renal function (serum creatinine>5 mg/dl), it is recommended that an infusion rate of 2.5 mg per minute is not exceeded. Intramuscular administration must ...
... Intravenous furosemide must be injected or infused slowly; a rate of 4 mg per minute must not be exceeded. In patients with severe impairment of renal function (serum creatinine>5 mg/dl), it is recommended that an infusion rate of 2.5 mg per minute is not exceeded. Intramuscular administration must ...
ABSTRACT Title of Dissertation: ENERGETICS OF DRUG INTERACTIONS
... become entropically-driven. These binding reactions also manifest enthalpy-entropy compensation where changes in the binding enthalpies are compensated by changes in the binding entropies. In drug binding to the more flexible p38α MAP kinase mutants, a single-point C→S mutation distal from the bind ...
... become entropically-driven. These binding reactions also manifest enthalpy-entropy compensation where changes in the binding enthalpies are compensated by changes in the binding entropies. In drug binding to the more flexible p38α MAP kinase mutants, a single-point C→S mutation distal from the bind ...
1.3.1 LEVITRA-Annotated PM dated 06-Mar-2015
... degenerative retinal disorders such as retinitis pigmentosa; its use is therefore not recommended until further information is available. Otologic Sudden decrease or loss of hearing has been reported in a few postmarketing and clinical trial cases with the use of PDE5 inhibitors, including LEVITRA. ...
... degenerative retinal disorders such as retinitis pigmentosa; its use is therefore not recommended until further information is available. Otologic Sudden decrease or loss of hearing has been reported in a few postmarketing and clinical trial cases with the use of PDE5 inhibitors, including LEVITRA. ...
Product Monograph
... number of patients (29) ranging in age from 1 day to 6 months have been treated safely with DIFLUCAN. Use in Elderly DIFLUCAN was well tolerated by patients aged 65 years and over. Fluconazole is primarily cleared by renal excretion as unchanged drug. Because elderly patients are more likely to have ...
... number of patients (29) ranging in age from 1 day to 6 months have been treated safely with DIFLUCAN. Use in Elderly DIFLUCAN was well tolerated by patients aged 65 years and over. Fluconazole is primarily cleared by renal excretion as unchanged drug. Because elderly patients are more likely to have ...
Aminoglycosides
... similar activity against most G-ve bacilli . - Tobramycin > active against P. aeruginosa & some proteus spec. (Amikacin & in some instances Netilmicin retain their act. against Gentamicin resistant strains because they are a poor substrate for many of the Amgl. inactivating enzymes.) ...
... similar activity against most G-ve bacilli . - Tobramycin > active against P. aeruginosa & some proteus spec. (Amikacin & in some instances Netilmicin retain their act. against Gentamicin resistant strains because they are a poor substrate for many of the Amgl. inactivating enzymes.) ...
AusPAR: Metformin HCI / Linagliptin
... including the innovator company Alphapharm Pty Ltd. The Australian innovator brand name is ‘Glucophage’ for the 500 and 850 mg tablets and ‘Diabex’ for the 1000 mg strength. This AusPAR describes the application by Boehringer Ingelheim Pty Ltd to register a fixed-dose combination tablet containing t ...
... including the innovator company Alphapharm Pty Ltd. The Australian innovator brand name is ‘Glucophage’ for the 500 and 850 mg tablets and ‘Diabex’ for the 1000 mg strength. This AusPAR describes the application by Boehringer Ingelheim Pty Ltd to register a fixed-dose combination tablet containing t ...
Levitra - GSK Source
... hours in duration) for this class of compounds, including vardenafil. In the event that an erection persists longer than 4 hours, the patient should seek immediate medical assistance. If priapism is not treated immediately, penile tissue damage and permanent loss of potency may result. LEVITRA shoul ...
... hours in duration) for this class of compounds, including vardenafil. In the event that an erection persists longer than 4 hours, the patient should seek immediate medical assistance. If priapism is not treated immediately, penile tissue damage and permanent loss of potency may result. LEVITRA shoul ...
PRODUCT MONOGRAPH OFLOXACIN TABLETS 200, 300 and 400 mg
... Convulsions, increased intracranial pressure, and toxic psychosis have been reported in patients receiving quinolones, including ofloxacin. Quinolones, including ofloxacin, may also cause central nervous system stimulation, which may lead to tremors, restlessness/agitation, nervousness/anxiety, ligh ...
... Convulsions, increased intracranial pressure, and toxic psychosis have been reported in patients receiving quinolones, including ofloxacin. Quinolones, including ofloxacin, may also cause central nervous system stimulation, which may lead to tremors, restlessness/agitation, nervousness/anxiety, ligh ...
INHIBITION OF OAT3-MEDIATED RENAL UPTAKE AS A
... of the renal clearance (Table 1). Simultaneously administered probenecid caused an approximately 50% increase in the AUC of fexofenadine in healthy subjects, and this is largely explained by a 73% inhibition of the renal clearance of fexofenadine (Table 1) (YasuiFurukori et al., 2005). In the presen ...
... of the renal clearance (Table 1). Simultaneously administered probenecid caused an approximately 50% increase in the AUC of fexofenadine in healthy subjects, and this is largely explained by a 73% inhibition of the renal clearance of fexofenadine (Table 1) (YasuiFurukori et al., 2005). In the presen ...
ranitidine oral
... excluded. Increases in blood alcohol concentrations have been noted in some studies in healthy individuals receiving ranitidine or some other H2 antagonists concomitantly with alcohol; however, conflicting data exist, which may be related to the effects of various patient-specific factors (e.g., gen ...
... excluded. Increases in blood alcohol concentrations have been noted in some studies in healthy individuals receiving ranitidine or some other H2 antagonists concomitantly with alcohol; however, conflicting data exist, which may be related to the effects of various patient-specific factors (e.g., gen ...
Comparison of Inhaled Corticosteroids: An Update
... short-term growth, 24-hour urinary free cortisol, and 24hour area under the curve (AUC0-24) for serum cortisol and serum osteocalcin, have been used to compare the potency of inhaled corticosteroids.22,32 However, as these effects are highly dependent on the differences in the delivery and pharmacok ...
... short-term growth, 24-hour urinary free cortisol, and 24hour area under the curve (AUC0-24) for serum cortisol and serum osteocalcin, have been used to compare the potency of inhaled corticosteroids.22,32 However, as these effects are highly dependent on the differences in the delivery and pharmacok ...
Esomeprazole
... porphyrinogenic; it should be used only when no safer alternative is available and precautions should be considered in vulnerable patients.1 (Last reviewed: 20131011; last modified: 20131017) 1. The Drug Database for Acute Porphyria. Available at: http://www.drugsporphyria.org (accessed 03/10/1 ...
... porphyrinogenic; it should be used only when no safer alternative is available and precautions should be considered in vulnerable patients.1 (Last reviewed: 20131011; last modified: 20131017) 1. The Drug Database for Acute Porphyria. Available at: http://www.drugsporphyria.org (accessed 03/10/1 ...
overview of comments received on community - EMA
... moderate depression, leads to the conclusion, that moderate depressive episodes are a necessary part of the therapeutic indication. With respect to the qualitative and quantitative composition, a limitation of well established use to preparations with hyperforin contents of at least 2 % seems to be ...
... moderate depression, leads to the conclusion, that moderate depressive episodes are a necessary part of the therapeutic indication. With respect to the qualitative and quantitative composition, a limitation of well established use to preparations with hyperforin contents of at least 2 % seems to be ...
STAXYN PRODUCT MONOGRAPH
... erection or if they have an undesirable effect as vardenafil in film-coated tablets are available in other strengths. Patients should be counselled about the importance of notifying their physicians about other medications they have been prescribed, including STAXYN. Physicians should counsel patien ...
... erection or if they have an undesirable effect as vardenafil in film-coated tablets are available in other strengths. Patients should be counselled about the importance of notifying their physicians about other medications they have been prescribed, including STAXYN. Physicians should counsel patien ...
Actions of bufalin and cinobufotalin, two bufadienolides respectively
... recently cinobufotalin has been reported to be less active than ouabain on this enzyme [8]. Ouabain is not the most toxic of the cardiac glycosides, but many studies have related activity of other molecules to that of ouabain, especially in relation to inhibition of Na+/K+-ATPase and the inhibition ...
... recently cinobufotalin has been reported to be less active than ouabain on this enzyme [8]. Ouabain is not the most toxic of the cardiac glycosides, but many studies have related activity of other molecules to that of ouabain, especially in relation to inhibition of Na+/K+-ATPase and the inhibition ...
Effects of different doses of venlafaxine on serotonin and
... resulting from 5-HT reuptake inhibition. This dose equivalency between these two drugs is, therefore, quite different from the 100-fold greater in-vitro potency of paroxetine when compared to that of venlafaxine (Béı̈que et al., 1998 ; Tatsumi et al., 1997). In a similar model indirectly assessing N ...
... resulting from 5-HT reuptake inhibition. This dose equivalency between these two drugs is, therefore, quite different from the 100-fold greater in-vitro potency of paroxetine when compared to that of venlafaxine (Béı̈que et al., 1998 ; Tatsumi et al., 1997). In a similar model indirectly assessing N ...
Martindale: The Complete Drug Reference
... Uses and Administration (Latest modification: 05-Sep-2009) Cefuroxime is a second-generation cephalosporin antibacterial used in the treatment of infections caused by susceptible Gram-positive and Gram-negative bacteria, including infections of the bones and joints, CNS, skin and skin structures, re ...
... Uses and Administration (Latest modification: 05-Sep-2009) Cefuroxime is a second-generation cephalosporin antibacterial used in the treatment of infections caused by susceptible Gram-positive and Gram-negative bacteria, including infections of the bones and joints, CNS, skin and skin structures, re ...
PRODUCT MONOGRAPH Pilocarpine Hydrochloride Tablets, USP
... Patients with mild and moderate hepatic impairment should begin treatment at a reduced daily dose, gradually increasing the dosage up to 5 mg three to four times daily as safety and tolerability allow. (See DOSAGE AND ADMINISTRATION). No pharmacokinetic data are available for any dose of pilocarpine ...
... Patients with mild and moderate hepatic impairment should begin treatment at a reduced daily dose, gradually increasing the dosage up to 5 mg three to four times daily as safety and tolerability allow. (See DOSAGE AND ADMINISTRATION). No pharmacokinetic data are available for any dose of pilocarpine ...
Synopsis of Some Recent Tactical Application of Bioisosteres in
... for the mechanism-based HCV NS3 protease inhibitor telaprevir (12).39 The (S)-R-ketoamide in 12 readily racemizes at higher pH and, most notably, in human plasma to afford the(R)diastereomer, which exhibits 30-fold weaker biological activity (Figure 2). The (R)-diastereomer of 12 is the primary meta ...
... for the mechanism-based HCV NS3 protease inhibitor telaprevir (12).39 The (S)-R-ketoamide in 12 readily racemizes at higher pH and, most notably, in human plasma to afford the(R)diastereomer, which exhibits 30-fold weaker biological activity (Figure 2). The (R)-diastereomer of 12 is the primary meta ...
Ketoconazole and Itraconazole Pharmacokinetic
... infections, skin and soft tissue infections and urethral or gonorrhoeal infections of the cervix (3). CIP is mainly excreted unchanged in the urine (4). However, dose adjustments were found to be necessary in patients with liver failure because of the significant non-renal clearance of ciprofloxacin ...
... infections, skin and soft tissue infections and urethral or gonorrhoeal infections of the cervix (3). CIP is mainly excreted unchanged in the urine (4). However, dose adjustments were found to be necessary in patients with liver failure because of the significant non-renal clearance of ciprofloxacin ...
Paritaprevir / Ritonavir / Ombitasvir and Dasabuvir
... combination packs with different strengths of ribavirin (Submission number PM-201401438-1-2). The data in these submissions overlap and was considered concurrently and therefore the AusPARs are mostly the same except for the administrative information, detailed description of the ribavirin component ...
... combination packs with different strengths of ribavirin (Submission number PM-201401438-1-2). The data in these submissions overlap and was considered concurrently and therefore the AusPARs are mostly the same except for the administrative information, detailed description of the ribavirin component ...
the PDF
... Donepezil + memantine (ADS-8704, Arimenda; Adamas Pharmaceuticals), a once-daily fixed dose combination extended release formulation, is currently tested in Phase II clinical trials. In May 2012, the FDA approved Phase III studies in an end-of-Phase II meeting. First clinical results were presented ...
... Donepezil + memantine (ADS-8704, Arimenda; Adamas Pharmaceuticals), a once-daily fixed dose combination extended release formulation, is currently tested in Phase II clinical trials. In May 2012, the FDA approved Phase III studies in an end-of-Phase II meeting. First clinical results were presented ...
ZOFRAN Tablets, Oral Solution and Injection PRODUCT MONOGRAPH
... There is no experience in patients who are clinically jaundiced. The clearance of an 8 mg intravenous dose of ZOFRAN® was significantly reduced and the serum half-life significantly prolonged in subjects with severe impairment of hepatic function. In patients with moderate or severe impairment of he ...
... There is no experience in patients who are clinically jaundiced. The clearance of an 8 mg intravenous dose of ZOFRAN® was significantly reduced and the serum half-life significantly prolonged in subjects with severe impairment of hepatic function. In patients with moderate or severe impairment of he ...
Coadministration of Oral Cyclosporin A Enables Oral Therapy with
... a single agent at a dose of 60 mg/m2 during course 1 and paclitaxel i.v. at a dose of 175 mg/m2 administered as a 3-h infusion during course 2. In the second part of the study, it was planned that eight evaluable patients would receive paclitaxel on two randomized occasions. On one occasion, they wo ...
... a single agent at a dose of 60 mg/m2 during course 1 and paclitaxel i.v. at a dose of 175 mg/m2 administered as a 3-h infusion during course 2. In the second part of the study, it was planned that eight evaluable patients would receive paclitaxel on two randomized occasions. On one occasion, they wo ...
Inderal (propranolol hydrochloride) Tablets Rx only
... The mechanism of the antimigraine effect of propranolol has not been established. Betaadrenergic receptors have been demonstrated in the pial vessels of the brain. The specific mechanism of propranolol's antitremor effects has not been established, but beta-2 (noncardiac) receptors may be involved. ...
... The mechanism of the antimigraine effect of propranolol has not been established. Betaadrenergic receptors have been demonstrated in the pial vessels of the brain. The specific mechanism of propranolol's antitremor effects has not been established, but beta-2 (noncardiac) receptors may be involved. ...
Discovery and development of direct thrombin inhibitors
Direct thrombin inhibitors (DTIs) are a class of anticoagulant drugs that can be used to prevent and treat embolisms and blood clots caused by various diseases. They inhibit thrombin, a serine protease which affects the coagulation cascade in many ways. DTIs have undergone rapid development since the 90's. With technological advances in genetic engineering the production of recombinant hirudin was made possible which opened the door to this new group of drugs. Before the use of DTIs the therapy and prophylaxis for anticoagulation had stayed the same for over 50 years with the use of heparin derivatives and warfarin which have some well known disadvantages. DTIs are still under development, but the research focus has shifted towards factor Xa inhibitors, or even dual thrombin and fXa inhibitors that have a broader mechanism of action by both inhibiting factor IIa (thrombin) and Xa. A recent review of patents and literature on thrombin inhibitors has demonstrated that the development of allosteric and multi-mechanism inhibitors might lead the way to a more safer anticoagulant.